ZYME:NASDAQ, Zymeworks Inc.
ZYME stock overview
Zymeworks Inc. (ZYME:NASDAQ) closed at $27.97 on October 26, 2026,
down 0.89% on the day.
The stock trades 10.8% below its 52-week high of $31.34
and 74.8% above its 52-week low of $16.00.
Over the past year, it gained 59.1%.
Zymeworks Inc. is part of the Health Care sector (Major Pharmaceuticals).
Key figures
- Price
- $27.97
- Day change
- -0.89%
- Volume
- 180,612
- Average volume
- 882,184
- Market cap
- 2B+
- 52-week range
- $16.00 – $31.34
- 50-day average
- $27.04
- 200-day average
- $25.09
Price action over the past year
In 252 trading sessions since October 23, 2025, ZYME closed higher on 127 days (50%).
Its best day was November 17, 2025 (+29.05%) and its worst was May 8, 2026 (-10.19%).
The stock moved 10% or more in a single session 2 times.
It opened at least 5% above the previous day's high 1 time.
Recent signals
ZYME news
-
Oct 24, 2026:
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
-
Oct 24, 2026:
Stocktwits Biotech Dealmaker: Gilead And Roche Double Down On Early-Stage Assets Over Full Buyouts This Week
-
Oct 23, 2026:
Zymeworks stock surges on $813M Roche licensing deal
-
Oct 23, 2026:
Zymeworks Signs Roche Deal with $55 Million Upfront, Up to $718 Million in Milestones
-
Oct 23, 2026:
Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3
-
Oct 19, 2026:
Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma
-
Oct 15, 2026:
Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results
-
Oct 9, 2026:
Zymeworks (ZYME) Could Be 39% Undervalued On 2026 Revenue Guidance And CIO Hire
About Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer.
Similar stocks
Find more stocks like ZYME with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.